BBLG - Bone Biologics Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
8.50
0.00 (0.00%)
At close: 1:21PM EDT
Stock chart is not supported by your current browser
Previous Close8.50
Open8.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.50 - 8.50
52 Week Range8.50 - 26.00
Volume240
Avg. Volume3
Market Cap260.802M
Beta (3Y Monthly)-2.13
PE Ratio (TTM)N/A
EPS (TTM)-0.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire

    Milberg Phillips Grossman LLP Announces Securities Class Action Lawsuit Against Bone Biologics Corporation

    The Private Securities Litigation Reform Act of 1995 ("PSLRA") permits any investor who is a member of the putative class to seek appointment as lead plaintiff. The lead plaintiff can select a law firm of its choice.

  • Business Wire

    Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia

    Bone Biologics Corp. (BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it received Human Research Ethics Committee (HREC) approval on March 20, 2019, for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The pilot study will evaluate the safety and effectiveness of NB1 in adult subjects with degenerative disc disease (DDD) at one level from L2-S1, who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion (TLIF). The study design has been previously reviewed by the US Food and Drug Administration’s (FDA’s) Division of Orthopedic Devices in a Pre-submission and is intended to support progression to a pivotal clinical study in the United States. The Therapeutic Goods Administration (TGA) in Australia will be notified of the conduct of the study through the Clinical Trial Notification Scheme. “This marks a significant milestone in the advancement of NELL-1/DBX®,” remarked Company Chief Operating Officer Jeffrey Frelick.

  • We're sorry this is all we were able to find about this topic.